단일클론항체(mAb) 치료 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of monoclonal antibody (mAb) therapy Market

The global monoclonal antibody (mAb) therapy market is experiencing rapid expansion driven by rising demand for targeted therapies and advancements in biotechnology. The market was valued at USD 300.67 billion in 2025 and is projected to grow to USD 343.99 billion in 2026, reaching USD 1,057.75 billion by 2034, exhibiting a strong CAGR of 15.07% during the forecast period.

Monoclonal antibodies are highly specific therapies used to treat chronic diseases such as cancer, autoimmune disorders, and infectious diseases. Their ability to target specific cells with minimal side effects has significantly increased their adoption globally. In 2025, North America dominated the market with a 48.00% share, supported by strong R&D investments and advanced healthcare infrastructure.

Market Trends

A key trend shaping the market is the growing number of strategic collaborations among pharmaceutical companies to develop innovative monoclonal antibody therapies. Partnerships between biotech firms and large pharmaceutical companies are accelerating drug discovery and commercialization.

Another major trend is the rapid expansion of biosimilars. As patents for blockbuster drugs expire, lower-cost biosimilars are entering the market, increasing accessibility and competition. Additionally, the COVID-19 pandemic accelerated research and emergency approvals for mAb therapies, further strengthening market growth.

Market Drivers

Rising Investment in Novel Therapeutics

Significant investments from both government bodies and private organizations are fueling innovation in monoclonal antibody therapies. Funding initiatives and R&D programs are supporting the development of next-generation biologics with improved efficacy.

Increasing Prevalence of Chronic Diseases

The growing burden of chronic diseases such as cancer and autoimmune disorders is a major growth driver. Monoclonal antibodies have become a preferred treatment due to their targeted action and effectiveness.

Popular drugs such as Humira, Herceptin, and Rituxan have achieved blockbuster status, significantly contributing to market expansion.

Favorable Reimbursement Policies

Improving healthcare reimbursement frameworks across developed and emerging economies are enhancing patient access to expensive biologic therapies, further boosting demand.

Market Restraints

Despite strong growth, the market faces challenges due to stringent regulatory approval processes. The development and approval of monoclonal antibodies involve complex clinical trials and strict quality standards, increasing time and cost.

Additionally, potential side effects and high manufacturing costs limit widespread adoption, particularly in price-sensitive regions.

Segmentation Analysis

By Type

The market is segmented into human, humanized, chimeric, and murine monoclonal antibodies. The human mAb segment dominated with a 42.40% share in 2026, driven by high demand and strong sales of leading biologics.

By Application

The cancer segment held the largest share of 54.46% in 2026, supported by the rising global cancer burden and increasing pipeline of oncology drugs. Autoimmune diseases and other therapeutic areas are also witnessing steady growth.

By Distribution Channel

The hospital pharmacy segment dominated with a 57.31% share in 2026, owing to better reimbursement policies and the need for professional administration of these therapies. Retail and online pharmacies are gradually expanding their presence.

Regional Insights

North America led the market with USD 144.32 billion in 2025, supported by high healthcare spending and strong research ecosystem.

Europe accounted for USD 67.61 billion in 2025, driven by favorable regulatory policies and increased adoption of biosimilars.

Asia Pacific is the fastest-growing region, with USD 50.99 billion in 2025, fueled by rising healthcare investments, increasing disease prevalence, and expanding patient base.

Latin America (USD 21.63 billion in 2025) and Middle East & Africa (USD 16.12 billion in 2025) are emerging markets showing steady growth due to improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive, with major players such as AbbVie Inc., F. Hoffmann-La Roche Ltd., Amgen Inc., and Novartis AG.

These companies focus on product innovation, biosimilar development, and strategic partnerships to strengthen their market position. Collaborations and acquisitions are key strategies to expand therapeutic pipelines and global reach.

Conclusion

The monoclonal antibody therapy market is set for remarkable growth, expanding from USD 300.67 billion in 2025 to USD 1,057.75 billion by 2034. The market is driven by rising chronic disease prevalence, strong R&D investments, and increasing adoption of targeted therapies.

The growing availability of biosimilars, technological advancements, and favorable reimbursement policies will further accelerate market expansion. However, regulatory challenges and high treatment costs remain key concerns.

Segmentation By Type

• Human mAb
• Humanized mAb
• Chimeric mAb
• Murine mAb

By Application

• Cancer
• Autoimmune Diseases
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (Type, Application, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (Type, Application, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia-Pacific (Type, Application, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (Type, Application, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, by Key Countries/Region, 2025
• 4.2. Patent Snapshot, by Key Players
• 4.3. Pipeline Analysis, by Key Players
• 4.4. New Product Launches, by Key Players
• 4.5. Key Industry Developments - Mergers, Acquisitions and Partnerships
• 4.6. Impact of COVID-19 on the Market

5. Global Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Human mAb
  • 5.1.2. Humanized mAb
  • 5.1.3. Chimeric mAb
  • 5.1.4. Murine mAb
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Cancer
  • 5.2.2. Autoimmune Diseases
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacy
  • 5.3.2. Retail Pharmacy
  • 5.3.3. Online Pharmacy
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Human mAb
  • 6.1.2. Humanized mAb
  • 6.1.3. Chimeric mAb
  • 6.1.4. Murine mAb
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Cancer
  • 6.2.2. Autoimmune Diseases
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacy
  • 6.3.2. Retail Pharmacy
  • 6.3.3. Online Pharmacy
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Human mAb
  • 7.1.2. Humanized mAb
  • 7.1.3. Chimeric mAb
  • 7.1.4. Murine mAb
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Cancer
  • 7.2.2. Autoimmune Diseases
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Online Pharmacy
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Human mAb
  • 8.1.2. Humanized mAb
  • 8.1.3. Chimeric mAb
  • 8.1.4. Murine mAb
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Cancer
  • 8.2.2. Autoimmune Diseases
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacy
  • 8.3.2. Retail Pharmacy
  • 8.3.3. Online Pharmacy
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Human mAb
  • 9.1.2. Humanized mAb
  • 9.1.3. Chimeric mAb
  • 9.1.4. Murine mAb
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Cancer
  • 9.2.2. Autoimmune Diseases
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacy
  • 9.3.2. Retail Pharmacy
  • 9.3.3. Online Pharmacy
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Human mAb
  • 10.1.2. Humanized mAb
  • 10.1.3. Chimeric mAb
  • 10.1.4. Murine mAb
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Cancer
  • 10.2.2. Autoimmune Diseases
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacy
  • 10.3.2. Retail Pharmacy
  • 10.3.3. Online Pharmacy
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub region
  • 10.4.1. South Africa
  • 10.4.2. GCC
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. AbbVie Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Merck & Co., Inc
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. F.Hoffmann-La Roche Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Johnson & Johnson Services, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Novartis AG
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Daiichi Sankyo Company, Limited
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Amgen Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. AstraZeneca
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)